Q4 2018 13F Holders as of 31 Dec 2018
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
90,438,636
-
Number of holders
-
151
-
Total 13F shares, excl. options
-
22,084,355
-
Shares change
-
-771,034
-
Total reported value, excl. options
-
$630,914,836
-
Value change
-
-$57,784,767
-
Put/Call ratio
-
205%
-
Number of buys
-
62
-
Number of sells
-
-90
-
Price
-
$28.57
Significant Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q4 2018
216 filings reported holding CRSP - CRISPR Therapeutics AG - Common Stock as of Q4 2018.
CRISPR Therapeutics AG - Common Stock (CRSP) has 151 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 22,084,355 shares
of 90,438,636 outstanding shares and own 24% of the company stock.
Largest 10 shareholders include Versant Venture Management, LLC (3,608,874 shares), NEA Management Company, LLC (2,090,678 shares), ARK Investment Management LLC (1,325,110 shares), FARALLON CAPITAL MANAGEMENT LLC (1,250,000 shares), Abingworth LLP (1,171,268 shares), WADDELL & REED FINANCIAL INC (1,000,000 shares), WELLINGTON MANAGEMENT GROUP LLP (841,438 shares), CREDIT SUISSE AG/ (774,873 shares), FEDERATED INVESTORS INC /PA/ (764,263 shares), and BlackRock Inc. (639,235 shares).
This table shows the top 151 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.